Assembly Biosciences, Inc. (NASDAQ:ASMB) Rating Lowered to Sell at Zacks Investment Research
Assembly Biosciences, Inc. (NASDAQ:ASMB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
Several other analysts have also commented on the company. BidaskClub raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday. Chardan Capital started coverage on Assembly Biosciences in a research note on Tuesday, May 30th. They issued a “buy” rating and a $35.00 price target on the stock.
Assembly Biosciences (NASDAQ ASMB) traded up 2.44% during midday trading on Monday, reaching $23.91. The company’s stock had a trading volume of 74,962 shares. The firm’s market capitalization is $415.17 million. The firm has a 50 day moving average price of $21.80 and a 200 day moving average price of $22.68. Assembly Biosciences has a 1-year low of $5.69 and a 1-year high of $28.24.
ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/14/assembly-biosciences-inc-nasdaqasmb-rating-lowered-to-sell-at-zacks-investment-research.html.
A number of institutional investors have recently bought and sold shares of the company. Jennison Associates LLC raised its position in Assembly Biosciences by 0.3% in the fourth quarter. Jennison Associates LLC now owns 2,025,870 shares of the biopharmaceutical company’s stock worth $15,214,000 after buying an additional 6,486 shares in the last quarter. Visium Asset Management LP raised its position in Assembly Biosciences by 6.2% in the fourth quarter. Visium Asset Management LP now owns 1,699,999 shares of the biopharmaceutical company’s stock worth $12,767,000 after buying an additional 99,998 shares in the last quarter. State Street Corp raised its position in Assembly Biosciences by 10.3% in the first quarter. State Street Corp now owns 158,273 shares of the biopharmaceutical company’s stock worth $799,000 after buying an additional 14,822 shares in the last quarter. Geode Capital Management LLC raised its position in Assembly Biosciences by 1.4% in the first quarter. Geode Capital Management LLC now owns 87,719 shares of the biopharmaceutical company’s stock worth $440,000 after buying an additional 1,180 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Assembly Biosciences by 167.2% in the first quarter. Renaissance Technologies LLC now owns 31,800 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 19,900 shares in the last quarter. 68.88% of the stock is currently owned by institutional investors.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.